Agiliti Announces Financial Results for Third Quarter 2021 and Raises Full Year 2021 Guidance
Agiliti Inc. (NYSE: AGTI) reported strong financial results for Q3 2021, achieving a 35% year-over-year revenue growth to $262 million. Net income rose to $9.7 million, a significant improvement from a net loss of $10.2 million last year. Adjusted EBITDA climbed 46% to $82 million. The company has raised its full-year revenue guidance to $1.01-$1.02 billion and adjusted EBITDA to $300-$310 million. Agiliti also completed the acquisition of Sizewise Rentals to enhance its service offerings.
- Revenue increased 35% year-over-year to $262 million.
- Net income improved to $9.7 million from a net loss of $10.2 million.
- Adjusted EBITDA grew 46% year-over-year to $82 million.
- Raised full-year revenue guidance to $1.01-$1.02 billion from $965-$980 million.
- Full-year adjusted EBITDA guidance increased to $300-$310 million from $280-$290 million.
- None.
Third Quarter 2021 Highlights
-
Revenue growth of 35 percent year-over-year to
$262 million -
Net income of
, up$9.7 million from the prior year period, and diluted income per share of$19.9 million , up$0.07 per share from the prior year period$0.17 -
Adjusted EBITDA1 growth of 46 percent year-over-year to
, and adjusted diluted earnings per share of$82 million , up$0.23 per share from the prior year period$0.10 -
Total debt of
; Net debt1 of$1,044.4 million ; Net Leverage ratio1 further reduced to 2.9x$920.7 million -
Raised full year 2021 guidance with expected revenue of
and Adjusted EBITDA of$1,010 -1,020 million 2$300 -310 million
“Our strong results from the quarter and our increased financial guidance for the year reflect the powerful fundamentals of our business” said
Third Quarter and Year-to-Date 2021 Financial Results
Total revenue for the three months ended
Net income for the three months ended
Adjusted EBITDA for the three months ended
Subsequent Events
On
2021 Financial Outlook
For the full year 2021, the Company now expects revenue to be in the range of
Conference Call Information
The conference call can be accessed live over the phone by dialing 1-877-300-8521 or for international callers, 1-412-317-6026. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 10160759. The replay will be available until
Interested investors and other parties may view a simultaneous webcast of the conference call by visiting the Agiliti Investor Relations site at https://investors.agilitihealth.com. The webcast replay will be available for a limited time shortly following the call.
About
Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
1 Non-GAAP Measures. See further discussion below.
2 With regard to the non-GAAP Adjusted EBITDA guidance provided above, a reconciliation to GAAP net income has not been provided as the quantification of certain items included in the calculation of GAAP net income cannot be calculated or predicted at this time without unreasonable efforts. For example, the non-GAAP adjustment for stock-based compensation expense requires additional inputs such as number of shares granted and market price that are not currently ascertainable, and the non-GAAP adjustment for certain reserves and expenses depends on the timing and magnitude of these expenses and cannot be accurately forecasted. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could have a potentially unpredictable, and potentially significant, impact on its future GAAP financial results.
Condensed Consolidated Statements of Operations | |||||||||||||
(in thousands, except share and per share information) | |||||||||||||
(unaudited) | |||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||
2021 |
2020 |
2021 |
2020 |
||||||||||
Revenue | $ | 262,424 |
$ | 194,721 |
|
$ | 748,212 |
$ | 559,121 |
|
|||
Cost of revenue | 158,990 |
120,115 |
|
444,346 |
359,239 |
|
|||||||
Gross margin | 103,434 |
74,606 |
|
303,866 |
199,882 |
|
|||||||
Selling, general and administrative | 75,052 |
71,732 |
|
225,334 |
180,838 |
|
|||||||
Operating income | 28,382 |
2,874 |
|
78,532 |
19,044 |
|
|||||||
Loss on extinguishment of debt | — |
— |
|
10,116 |
— |
|
|||||||
Interest expense | 10,711 |
13,560 |
|
40,444 |
46,532 |
|
|||||||
Income (loss) before income taxes and noncontrolling interest | 17,671 |
(10,686 |
) |
27,972 |
(27,488 |
) |
|||||||
Income tax expense (benefit) | 7,943 |
(573 |
) |
13,832 |
(5,678 |
) |
|||||||
Consolidated net income (loss) | 9,728 |
(10,113 |
) |
14,140 |
(21,810 |
) |
|||||||
Net income attributable to noncontrolling interest | 60 |
95 |
|
117 |
198 |
|
|||||||
Net income (loss) attributable to |
$ | 9,668 |
$ | (10,208 |
) |
$ | 14,023 |
$ | (22,008 |
) |
|||
Basic income (loss) per share | $ | 0.07 |
$ | (0.10 |
) |
$ | 0.12 |
$ | (0.22 |
) |
|||
Diluted income (loss) per share | $ | 0.07 |
$ | (0.10 |
) |
$ | 0.11 |
$ | (0.22 |
) |
|||
Weighted-average common shares outstanding: | |||||||||||||
Basic | 130,380,551 |
98,983,296 |
|
117,578,750 |
98,973,853 |
|
|||||||
Diluted | 138,490,526 |
98,983,296 |
|
125,515,000 |
98,973,853 |
|
|||||||
Condensed Consolidated Balance Sheets | ||||||||
(in thousands, except share and per share information) | ||||||||
(unaudited) | ||||||||
|
|
|||||||
2021 |
2020 |
|||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 123,713 |
|
$ | 206,505 |
|
||
Accounts receivable, less allowance for doubtful accounts of |
200,779 |
|
154,625 |
|
||||
Inventories | 29,092 |
|
27,062 |
|
||||
Other current assets | 14,847 |
|
14,175 |
|
||||
Total current assets | 368,431 |
|
402,367 |
|
||||
Property and equipment: | ||||||||
Medical equipment | 301,189 |
|
285,723 |
|
||||
Property and office equipment | 140,138 |
|
112,646 |
|
||||
Accumulated depreciation | (251,530 |
) |
(183,953 |
) |
||||
Total property and equipment, net | 189,797 |
|
214,416 |
|
||||
Other long-term assets: | ||||||||
1,122,530 |
|
817,113 |
|
|||||
Operating lease right-of-use assets | 56,692 |
|
51,214 |
|
||||
Other intangibles, net | 528,119 |
|
402,095 |
|
||||
Other | 18,884 |
|
16,151 |
|
||||
Total assets | $ | 2,284,453 |
|
$ | 1,903,356 |
|
||
Liabilities and Equity | ||||||||
Current liabilities: | ||||||||
Current portion of long-term debt | $ | 15,849 |
|
$ | 16,044 |
|
||
Current portion of operating lease liability | 15,607 |
|
14,155 |
|
||||
Current portion of obligation under tax receivable agreement | 15,691 |
|
15,572 |
|
||||
Accounts payable | 48,712 |
|
37,215 |
|
||||
Accrued compensation | 37,658 |
|
38,671 |
|
||||
Accrued interest | 2,784 |
|
6,347 |
|
||||
Deferred revenue | 6,858 |
|
8,800 |
|
||||
Other accrued expenses | 24,111 |
|
22,727 |
|
||||
Total current liabilities | 167,270 |
|
159,531 |
|
||||
Long-term debt, less current portion | 1,028,626 |
|
1,145,055 |
|
||||
Obligation under tax receivable agreement, pension and other long-term liabilities | 57,216 |
|
53,794 |
|
||||
Operating lease liability, less current portion | 45,919 |
|
40,283 |
|
||||
Deferred income taxes, net | 109,469 |
|
62,748 |
|
||||
Commitments and contingencies (Note 11) | ||||||||
Equity | ||||||||
Common stock, |
13 |
|
10 |
|
||||
Additional paid-in capital | 932,867 |
|
513,902 |
|
||||
Accumulated deficit | (54,469 |
) |
(68,492 |
) |
||||
Accumulated other comprehensive loss | (2,581 |
) |
(3,619 |
) |
||||
875,830 |
|
441,801 |
|
|||||
Noncontrolling interest | 123 |
|
144 |
|
||||
Total equity | 875,953 |
|
441,945 |
|
||||
Total liabilities and equity | $ | 2,284,453 |
|
$ | 1,903,356 |
|
Condensed Consolidated Statements of Cash Flows | ||||||||
(in thousands, except share and per share information) | ||||||||
(unaudited) | ||||||||
Nine Months Ended | ||||||||
2021 |
2020 |
|||||||
Cash flows from operating activities: | ||||||||
Consolidated net income (loss) | $ | 14,140 |
|
$ | (21,810 |
) |
||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
Depreciation | 78,249 |
|
72,955 |
|
||||
Amortization | 63,482 |
|
54,536 |
|
||||
Remeasurement of tax receivable agreement and contingent consideration | 4,542 |
|
8,231 |
|
||||
Loss on extinguishment of debt | 7,716 |
|
— |
|
||||
Provision for doubtful accounts | 1,121 |
|
1,336 |
|
||||
Provision for inventory obsolescence | 2,539 |
|
458 |
|
||||
Non-cash share-based compensation expense | 10,127 |
|
7,657 |
|
||||
Gain on sales and disposals of equipment | (3,939 |
) |
(852 |
) |
||||
Deferred income taxes | 12,040 |
|
(5,967 |
) |
||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (30,305 |
) |
(37,618 |
) |
||||
Inventories | 1,241 |
|
(5,534 |
) |
||||
Other operating assets | (5,392 |
) |
(6,431 |
) |
||||
Accounts payable | 4,701 |
|
(1,138 |
) |
||||
Other operating liabilities | (21,849 |
) |
33,903 |
|
||||
Net cash provided by operating activities | 138,413 |
|
99,726 |
|
||||
Cash flows from investing activities: | ||||||||
Medical equipment purchases | (23,912 |
) |
(22,806 |
) |
||||
Property and office equipment purchases | (15,539 |
) |
(15,465 |
) |
||||
Proceeds from disposition of property and equipment | 8,187 |
|
2,157 |
|
||||
Acquisitions, net of cash acquired | (450,198 |
) |
(89,706 |
) |
||||
Net cash used in investing activities | (481,462 |
) |
(125,820 |
) |
||||
Cash flows from financing activities: | ||||||||
Proceeds under revolver | 35,000 |
|
249,500 |
|
||||
Payments under revolver | (35,000 |
) |
(283,000 |
) |
||||
Proceeds under term loan | 198,052 |
|
124,844 |
|
||||
Payments under term loan | (326,770 |
) |
(5,895 |
) |
||||
Payments of principal under finance lease liability | (6,721 |
) |
(6,312 |
) |
||||
Payments of deferred financing costs | (229 |
) |
(199 |
) |
||||
Payments under tax receivable agreement | (748 |
) |
— |
|
||||
Distributions to noncontrolling interests | (138 |
) |
(322 |
) |
||||
Proceeds from exercise of stock options | 380 |
|
— |
|
||||
Dividend and equity distribution payment | (926 |
) |
(1,138 |
) |
||||
Proceeds from issuance of common stock | 401,441 |
|
— |
|
||||
Stock issuance costs | (4,084 |
) |
— |
|
||||
Shares forfeited for taxes | — |
|
(145 |
) |
||||
Change in book overdrafts | — |
|
(1,771 |
) |
||||
Net cash provided by financing activities | 260,257 |
|
75,562 |
|
||||
Net change in cash and cash equivalents | (82,792 |
) |
49,468 |
|
||||
Cash and cash equivalents at the beginning of period | 206,505 |
|
— |
|
||||
Cash and cash equivalents at the end of period | $ | 123,713 |
|
$ | 49,468 |
|
||
Supplemental cash flow information: | ||||||||
Interest paid | $ | 40,991 |
|
$ | 41,279 |
|
||
Income taxes paid | 2,647 |
|
1,007 |
|
||||
Use of non-GAAP information
This press release contains non-GAAP measures, including EBITDA, Adjusted EBITDA, Adjusted EPS and Net Leverage Ratio. We use these internally as measures of operational performance and disclose them externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. We believe the investment community frequently uses these measures in the evaluation of similarly situated companies. Adjusted EBITDA is also used by the Company as a factor to determine the total amount of incentive compensation to be awarded to executive officers and other employees. EBITDA, Adjusted EBITDA, Adjusted EPS and Net Leverage Ratio, however, are not measures of financial performance under accounting principles generally accepted in
Adjusted EBITDA | ||||||||||||||
(unaudited) | ||||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||
|
|
|||||||||||||
(in thousands) | 2021 |
2020 |
2021 |
2020 |
||||||||||
Net income (loss) attributable to |
$ | 9,668 |
$ | (10,208 |
) |
$ | 14,023 |
$ | (22,008 |
) |
||||
Interest expense | 10,711 |
13,560 |
|
40,444 |
46,532 |
|
||||||||
Income tax expense (benefit) | 7,943 |
(573 |
) |
13,832 |
(5,678 |
) |
||||||||
Depreciation and amortization | 46,860 |
42,597 |
|
138,676 |
124,659 |
|
||||||||
EBITDA | 75,183 |
45,376 |
|
206,975 |
143,505 |
|
||||||||
Non-cash share-based compensation expense | 4,360 |
3,206 |
|
10,127 |
7,657 |
|
||||||||
Management and other expenses (1) | — |
(3,266 |
) |
7,626 |
(256 |
) |
||||||||
Transaction costs (2) | 2,189 |
1,137 |
|
6,440 |
1,699 |
|
||||||||
Tax receivable agreement remeasurement | 197 |
9,600 |
|
4,542 |
9,600 |
|
||||||||
Loss on extinguishment of debt (3) | — |
— |
|
10,116 |
— |
|
||||||||
Adjusted EBITDA | $ | 81,929 |
$ | 56,053 |
|
$ | 245,826 |
$ | 162,205 |
|
(1) Management and other expenses represent (a) management fees and buyout termination fee under the Advisory Services Agreement, which was terminated in connection with the initial public offering and (b) employee related non-recurring expenses.
(2) Transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the
(3) Loss on extinguishment of debt consists of the write-off of the unamortized deferred financing costs and debt discount and an additional
Non-GAAP Financial Measure: Adjusted EPS | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three months ended | Nine months ended | |||||||||||||||
(in thousands) | 2021 |
2020 |
2021 |
2020 |
||||||||||||
Net income (loss) attributable to |
$ |
9,668 |
|
$ |
(10,208 |
) |
$ |
14,023 |
|
$ |
(22,008 |
) |
||||
and Subsidiaries | ||||||||||||||||
Amortization |
|
21,497 |
|
|
17,558 |
|
|
60,427 |
|
|
51,702 |
|
||||
Non-cash share-based compensation expense |
|
4,360 |
|
|
3,206 |
|
|
10,127 |
|
|
7,657 |
|
||||
Management and other expenses (1) |
|
- |
|
|
(3,266 |
) |
|
7,626 |
|
|
(256 |
) |
||||
Transaction costs (2) |
|
2,189 |
|
|
1,137 |
|
|
6,440 |
|
|
1,699 |
|
||||
Tax receivable agreement remeasurement(3) |
|
197 |
|
|
9,600 |
|
|
4,542 |
|
|
9,600 |
|
||||
Loss on extinguishment of debt (4) |
|
- |
|
|
- |
|
|
10,116 |
|
|
- |
|
||||
Income tax benefit associated with pre-tax adjustments (5) |
|
(6,724 |
) |
|
(4,733 |
) |
|
(20,452 |
) |
|
(15,527 |
) |
||||
Adjusted Net Income | $ |
31,187 |
|
$ |
13,294 |
|
$ |
92,849 |
|
$ |
32,867 |
|
||||
Weighted average shares outstanding - diluted |
|
138,491 |
|
|
103,706 |
|
|
125,515 |
|
|
103,680 |
|
||||
Adjusted EPS | $ |
0.23 |
|
$ |
0.13 |
|
$ |
0.74 |
|
$ |
0.32 |
|
(1) Management and other expenses represent (a) management fees and buyout termination fee under the Advisory Services Agreement, which was terminated in connection with the initial public offering and (b) employee related non-recurring expenses. (2) Transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the
Non-GAAP Financial Measure: Net Leverage Ratio | ||||
(unaudited) | ||||
|
||||
(in millions) | 2021 |
|||
Term Loan B (due 2026) | $ |
1,035.4 |
|
|
Consolidated Capital Leases |
|
26.1 |
|
|
Less: Deferred Financing Fees |
|
(17.1 |
) |
|
Debt | $ |
1,044.4 |
|
|
Less: Cash |
|
(123.7 |
) |
|
Net Debt | $ |
920.7 |
|
|
LTM Adjusted EBITDA | $ |
317.8 |
|
|
Net Leverage | 2.9x |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006341/en/
Corporate Communication and Investor Relations
kate.kaiser@agilitihealth.com
Source:
FAQ
What were Agiliti's Q3 2021 revenue results?
How much did Agiliti earn in Q3 2021?
What is Agiliti's updated full-year guidance for 2021?
What acquisition did Agiliti complete recently?